市場調查報告書
商品編碼
997578

疫苗佐劑的全球市場

Vaccine Adjuvants

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 329 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球疫苗佐劑的市場規模,預計在分析期間(2020年∼2027年)將以9.1%的年複合成長率增長,從2020年的5億6,080萬美元,到2027年達到10億美元。

本報告所分析的市場區隔之一的粒子狀佐劑部門,在分析期間中預計將以9.3%的年複合成長率增長,達到3億4,930萬美元。

本報告提供全球疫苗佐劑市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Agenus, Inc.
  • Avanti Polar Lipids, Inc.
  • Brenntag Biosector A/S
  • CSL Ltd.
  • Invivogen
  • Mvp Laboratories Inc.
  • Novavax, Inc.
  • OZ Biosciences SAS
  • Seppic SA
  • SPI Pharma

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:44公司
目錄
Product Code: MCP15427

Abstract:

Global Vaccine Adjuvants Market to Reach $1 Billion by 2027

Amid the COVID-19 crisis, the global market for Vaccine Adjuvants estimated at US$560.8 Million in the year 2020, is projected to reach a revised size of US$1 Billion by 2027, growing at a CAGR of 9.1% over the analysis period 2020-2027. Particulate Adjuvants, one of the segments analyzed in the report, is projected to record a 9.3% CAGR and reach US$349.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adjuvant Emulsions segment is readjusted to a revised 10.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $166.2 Million, While China is Forecast to Grow at 8.5% CAGR

The Vaccine Adjuvants market in the U.S. is estimated at US$166.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$178.9 Million by the year 2027 trailing a CAGR of 8.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Pathogen Components Segment to Record 8.2% CAGR

In the global Pathogen Components segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$85.1 Million in the year 2020 will reach a projected size of US$148.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$119.4 Million by the year 2027.

Select Competitors (Total 44 Featured) -

  • Agenus, Inc.
  • Avanti Polar Lipids, Inc.
  • Brenntag Biosector A/S
  • CSL Ltd.
  • Invivogen
  • Mvp Laboratories Inc.
  • Novavax, Inc.
  • OZ Biosciences SAS
  • Seppic SA
  • SPI Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Vaccine Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Particulate Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Particulate Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Particulate Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Adjuvant Emulsions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Adjuvant Emulsions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Adjuvant Emulsions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Pathogen Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Pathogen Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Pathogen Components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Combination Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Combination Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Combination Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Intranasal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Intranasal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Intranasal Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 49: World Current & Future Analysis for Human Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 50: World Historic Review for Human Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: World 15-Year Perspective for Human Vaccine Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 52: World Current & Future Analysis for Veterinary Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 53: World Historic Review for Veterinary Vaccine Adjuvants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: World 15-Year Perspective for Veterinary Vaccine Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 55: USA Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 58: USA Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: USA Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: USA 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 61: USA Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: USA Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: USA 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 64: USA Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: USA Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: USA 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 67: USA Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: USA Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: USA 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 70: Canada Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Canada Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Canada 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 73: Canada Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Canada Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Canada 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 76: Canada Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Canada Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Canada 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 79: Canada Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Canada Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Canada 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 82: Canada Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Canada Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Canada 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 85: Japan Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Japan Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Japan 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 88: Japan Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Japan Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Japan 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 91: Japan Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Japan Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Japan 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 94: Japan Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Japan Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Japan 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 97: Japan Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Japan Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Japan 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 100: China Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: China Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: China 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 103: China Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: China Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: China 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 106: China Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: China Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: China 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 109: China Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: China Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: China 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 112: China Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: China Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: China 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 115: Europe Current & Future Analysis for Vaccine Adjuvants by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 116: Europe Historic Review for Vaccine Adjuvants by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Europe 15-Year Perspective for Vaccine Adjuvants by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 118: Europe Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Europe Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Europe 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 121: Europe Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Europe Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Europe 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 124: Europe Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Europe Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Europe 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 127: Europe Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Europe Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Europe 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 130: Europe Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Europe Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Europe 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 133: France Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: France Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: France 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 136: France Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: France Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: France 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 139: France Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: France Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: France 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 142: France Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: France Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: France 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 145: France Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: France Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: France 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 148: Germany Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Germany Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Germany 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 151: Germany Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Germany Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Germany 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 154: Germany Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Germany Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Germany 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 157: Germany Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Germany Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Germany 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 160: Germany Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Germany Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Germany 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 163: Italy Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Italy Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Italy 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 166: Italy Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Italy Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Italy 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 169: Italy Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Italy Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Italy 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 172: Italy Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Italy Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Italy 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 175: Italy Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Italy Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Italy 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 178: UK Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: UK Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: UK 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 181: UK Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: UK Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: UK 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 184: UK Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: UK Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: UK 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 187: UK Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: UK Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: UK 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 190: UK Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: UK Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: UK 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 193: Rest of Europe Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Europe Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Europe 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Europe Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Europe Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Europe 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 199: Rest of Europe Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Europe Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of Europe 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 202: Rest of Europe Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Europe Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Europe 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Europe Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Rest of Europe Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Rest of Europe 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 208: Asia-Pacific Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Asia-Pacific Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Asia-Pacific 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 211: Asia-Pacific Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Asia-Pacific Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Asia-Pacific 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 214: Asia-Pacific Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Asia-Pacific Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Asia-Pacific 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 217: Asia-Pacific Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Asia-Pacific Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Asia-Pacific 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 220: Asia-Pacific Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Asia-Pacific Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Asia-Pacific 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 223: Rest of World Current & Future Analysis for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Rest of World Historic Review for Vaccine Adjuvants by Type - Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Rest of World 15-Year Perspective for Vaccine Adjuvants by Type - Percentage Breakdown of Value Sales for Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Combination Adjuvants and Other Types for the Years 2012, 2020 & 2027
    • TABLE 226: Rest of World Current & Future Analysis for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Rest of World Historic Review for Vaccine Adjuvants by Route Of Administration - Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: Rest of World 15-Year Perspective for Vaccine Adjuvants by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intranasal Route, Oral Route and Other Route of Administrations for the Years 2012, 2020 & 2027
    • TABLE 229: Rest of World Current & Future Analysis for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Rest of World Historic Review for Vaccine Adjuvants by Disease Type - Infectious Diseases, Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: Rest of World 15-Year Perspective for Vaccine Adjuvants by Disease Type - Percentage Breakdown of Value Sales for Infectious Diseases, Cancer and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 232: Rest of World Current & Future Analysis for Vaccine Adjuvants by Application - Research and Commercial - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Rest of World Historic Review for Vaccine Adjuvants by Application - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: Rest of World 15-Year Perspective for Vaccine Adjuvants by Application - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2012, 2020 & 2027
    • TABLE 235: Rest of World Current & Future Analysis for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of World Historic Review for Vaccine Adjuvants by Application Category - Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of World 15-Year Perspective for Vaccine Adjuvants by Application Category - Percentage Breakdown of Value Sales for Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44